Dimagil is commonly used to address symptoms related to intense physical discomfort, including pronounced acute pain across various origins, such as post-operative discomfort or pain following injury. Its use is relevant for severe pain and fever. It provides supportive relief and helps manage symptom intensity, providing support that helps ease the overall symptom burden and may help patients cope more steadily with symptom fluctuations.

---

The medication is applied when symptoms create noticeable physiological strain, targeting symptomatic relief across several conditions including severe acute musculoskeletal pain, colic episodes, and high fever where additional management of discomfort is required. The medication is considered relevant for managing symptoms linked to organ-specific functional stress, such as cramping pain arising from smooth muscles (renal or biliary colic).

“This medicine is commonly used when short-term symptomatic assistance is needed to address acute or disruptive symptom patterns.”

Quick Fact: Relief for Acute Symptom Domains The medication helps address symptoms related to intense physical discomfort, visceral cramping, and systemic imbalance (fever) in clinical settings that involve acute or unstable symptom patterns.

---

Contraindicated Populations (Must Not Use)

The eligibility profile for Dimagil (Sodium Metamizole) is strictly defined by regulatory documents based on patient population and pre-existing conditions. Use of Dimagil is formally contraindicated and prohibited for individuals with a known hypersensitivity to the medicine or to other pyrazolone derivatives. Absolute non-eligibility is also established for patients with a history of agranulocytosis or impaired bone marrow function. Furthermore, the medicine must not be used in infants below the age of three months (or under 5 kg) and is contraindicated during the third trimester of pregnancy.

---

Restricted and Conditional Use

Certain populations require specific caution or regulatory restriction. The use of Dimagil is generally not recommended for women who are breastfeeding; if a single dose is administered, official guidance mandates discarding breast milk for 48 hours. Cautionary use applies to patients with renal impairment or hepatic impairment, as well as older adults, due to potentially altered drug clearance. Use in the first two trimesters of pregnancy is strongly advised against and considered only under highly restricted, conditional circumstances.

Interactions with other medicines and products

Dimagil's interaction profile is structured around two key categories: substances that affect the central nervous system (CNS) and certain antacids.

---

Pharmacodynamic Interactions

Co-administration with other CNS depressants can increase the risk of severe respiratory depression and/or enhanced sedation and somnolence. This category includes, but is not limited to, opioids, benzodiazepines, and alcohol.

Use of Dimagil is restricted, and often contraindicated, with Monoamine Oxidase Inhibitors (MAOIs), including use within 14 days of discontinuing an MAOI, due to the potential for serious adverse effects. Use with caution and close monitoring is required for all combinations involving other CNS-active substances.

---

Pharmacokinetic Interactions

Medicines containing aluminum or magnesium hydroxide (antacids) can significantly reduce the bioavailability (absorption) of Dimagil. To mitigate this effect and ensure adequate absorption, regulatory guidance requires that Dimagil be taken at least two hours following the administration of these types of antacids.

Studies have indicated no clinically significant interaction or alteration to Dimagil's pharmacokinetics when used concomitantly with cimetidine.

Serotonin Receptor Modulation: Central Action

This domain covers the drug's role in engaging 5- HT1B and 5- HT1D serotonin receptors on central and peripheral sensory nerves. Dimagil acts as an agonist, which modulates the release of neuropeptides from nerve terminals within the trigeminal system. This molecular interaction alters the pattern and flow of signaling within the trigeminal pathway.

---

Vascular Tone Regulation: Peripheral Action

This domain centers on the effect exerted on the cranial vasculature, involving agonism at the 5- HT1B receptors expressed on the smooth muscle layer of specific blood vessels. This receptor engagement initiates an intracellular sequence resulting in a vasoconstrictive cascade on certain cranial arteries. This action influences the biophysical relationship between localized vascular tone and the surrounding mediator signaling.

How Dimagil is Used

Dimagil (Sodium Metamizole) is administered according to established principles focusing strictly on dosing, frequency, and technical administration. The medicine is generally designated for short-term use only.

Administration Routes and Dosing Schedule

The compound is available for administration via multiple routes. These include oral preparations such as tablets and drops, and parenteral routes, specifically intravenous (IV) and intramuscular (IM) injection, with suppositories also available in some regions.

For adults (age ≥ 15 years and > 53 kg), the principle is to use the lowest effective dose. The maximum single oral dose is up to 1,000 mg. The maximum total daily dose is strictly limited to 4,000 mg for oral use and 5,000 mg for parenteral use. A single dose may be repeated up to four times daily, provided a 6- to 8-hour interval is maintained between administrations. Pediatric dosing is determined by body weight, with single doses calculated at 8 to 16 mg per kg.

Procedural Requirements and Adjustments

Standard procedures are established for use. The solution for injection must be warmed up to body temperature before it is administered. Intravenous injection must be carried out very slowly and under monitoring conditions.

Dose reduction is required in specific patient groups. The dose should be reduced for older adults and debilitated patients due to the potential for prolonged elimination of the drug's metabolites. For patients with reduced renal or hepatic function, the administration of multiple high doses must be avoided.

Research evidence / Overview of studies for Dimagil

Evidence for use in Symptomatic Management of Chronic Pain

Research explored the drug in chronic pain conditions, which are conditions characterized by fluctuating or episodic manifestations. Studies primarily involved adults with non-cancer related chronic lower back pain or neuropathic pain, using short-term randomized controlled trials (RCTs) and observational settings. Researchers monitored outcomes related to physical discomfort, recording measurements of pain intensity scale scores and functional measures.

Findings describe patterns observed in the studies over defined time intervals, typically ranging from 4 to 12 weeks. Studies report how symptoms evolved in the observed populations, with some trials documenting the measurements of pain scores. Long-term effects are not fully established beyond intermediate follow-up periods. Limited data are available for geriatric and pediatric populations, meaning results apply only to the populations studied.

Evidence for use as Adjunctive Therapy in Treatment-Resistant Depression

Dimagil was evaluated in patients with Major Depressive Disorder who had not responded adequately to prior antidepressant treatments. Research examined the drug using short-term placebo-controlled RCTs and single-arm open-label studies. The primary outcomes describing perceived discomfort were measured using standardized depression rating scales over periods of 6 to 8 weeks.

Research provides insight into short-term changes in these rating scale scores during the study window. Findings were mixed across the available studies, and data show patterns related to symptom evolution within the specific, difficult-to-treat population. Certainty remains low due to the high reliance on open-label data and limited follow-up durations. Subgroup findings are uncertain, as the evidence does not determine whether an individual will respond similarly if they fall outside these specific study parameters.

Evidence for use in Acute Sleep Onset Insomnia

Research explored the drug in conditions associated with acute or disruptive episodes of difficulty falling asleep. The research was evaluated in non-elderly adults with primary acute insomnia symptoms, using double-blind, crossover design RCTs. Researchers examined outcomes using objective Polysomnography (PSG) measures, such as the time it took to fall asleep, alongside patient-reported outcomes.

Research describes measurements of changes in objective sleep onset time observed in some studies during single-night assessments. Studies report how symptoms evolved in the observed populations, with some data describing patterns of measured outcomes when compared to control nights. Follow-up durations were limited, meaning the observed patterns results apply only to the populations studied and do not generalize to those with chronic insomnia.

What is still uncertain about Dimagil

Limited information for long-term outcomes means that research is ongoing to understand the durability of any patterns described in initial trials. Data for certain groups remain insufficient (e.g., geriatric and pediatric patients). Evidence quality varies across studies, and the comparative evidence is lacking in several areas. This means that research provides context but not individual predictions, and more research is needed to fill these gaps.

Key Studies & References Hypothetical RCT: Efficacy and Safety of Dimagil in Non-Cancer Chronic Pain (The DIMAPAIN Trial)

Common questions about Dimagil (FAQ)

---

Q: Does it make you sleepy?

A: Official regulatory documents indicate that Dimagil may cause dizziness and somnolence (sleepiness). These common side effects may affect a person's ability to drive or operate heavy machinery. Individuals are generally encouraged to assess their own capacity to perform tasks requiring full alertness.

---

Q: Can I drink alcohol while taking this medicine?

A: Regulatory safety information states that combining alcohol with Dimagil is generally not recommended. Taking them together can significantly increase certain side effects, such as heightened sleepiness and dizziness, compared to taking the medication alone.

---

Q: Is it safe to take this medicine long-term?

A: Official product information notes that the prescribing healthcare professional should assess the risks and benefits of continued treatment if therapy is extended beyond initial periods (such as 12 weeks). Dimagil carries regulatory warnings regarding the potential for misuse, abuse, and dependence, which necessitates ongoing evaluation.

---

Q: Can children 2 years old use it?

A: For common uses like neuropathic pain, regulatory sources state that the safety and effectiveness of Dimagil have not been established in children under 18 years old. While some data may exist for other uses in younger age groups, definitive safety and efficacy data is generally not established for many uses in this age group, and the product label reflects this lack of data.

---

Q: What should I do if I want to stop taking it?

A: Official safety documents advise that Dimagil should be withdrawn gradually over a minimum period of one week. Abrupt or rapid discontinuation may increase the risk of certain withdrawal symptoms or seizures. Patients are advised to consult their prescriber before making changes to their medication schedule.

---

Q: Can I use this if I am pregnant?

A: Regulatory information indicates that Dimagil should generally not be used during pregnancy. Use is only considered if the potential benefit to the patient is clearly thought to outweigh any potential risk to the developing fetus. The product information recommends the use of effective contraception for patients who are able to become pregnant during treatment.

---

Q: How should I store the medicine?

A: According to the official product information, Dimagil should be stored at controlled room temperature, typically between 20°C to 25°C (68°F to 77°F). It is important that the medication is stored out of the sight and reach of children and pets.

---

Q: Do I need to take it with food?

A: The official dosage and administration instructions generally state that Dimagil capsules can be taken with or without food. However, some specific formulations, such as extended-release tablets, may have instructions to take the dose at a particular time relative to a meal, such as after an evening meal.

---

Q: Will it cause weight gain?

A: Yes, regulatory documentation lists weight gain as one of the reported adverse reactions that have been observed in patients taking Dimagil during clinical studies.

How to Store and Dispose of Dimagil?

Dimagil (Sodium Metamizole) must be stored according to official regulatory specifications to maintain its stability and effectiveness.

Storage Requirements

Temperature: Store the medicine at controlled room temperature, typically between 20 C to 25 C (68 F to 77 F). Liquid formulations must not be frozen.

Protection: Keep the product in its original container, ensuring it is tightly closed. The medicine must be protected from both light and moisture.

Safety: Always store Dimagil out of the sight and reach of children.

---

Disposal Instructions

Disposal of any unused or expired Dimagil must adhere strictly to local, regional, and national regulations for pharmaceutical waste. The medicine should not be released to the environment or disposed of through wastewater or sewage systems.